Easton Biopharmaceuticals Gets Registration Certificate for Apalutamide Tablets; Shares Slip 3%

MT Newswires

Chengdu Easton Biopharmaceuticals' apalutamide tablets received a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Friday.

The drug was originally developed by Johnson & Johnson unit Janssen Pharmaceuticals to treat adult patients with metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancers, the pharmaceutical company said.

The company's shares fell less than 3% in recent trade.

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Easton Biopharmaceuticals Gets Registration Certificate for Axitinib Tablets; Shares Down 3%

MT Newswires

688513

-1.93%

Chengdu Easton Biopharmaceuticals' axitinib tablets received a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Friday.

The drug was originally developed by Pfizer to treat adult patients with advanced renal cell carcinoma, who have failed prior treatment with one tyrosine kinase inhibitor or cytokine therapy, the pharmaceutical company said.

The company's shares fell less than 3% in recent trade.

Risk Warnings and Disclaimers

Add to Favorites

Easton Biopharmaceuticals Gets China's Regulatory Approval for Psychotropic Drug

MT Newswires

688513

-1.93%

Chengdu Easton Biopharmaceuticals received regulatory approval from China's medical products administrator for its Oxazepam tablets.

The psychotropic drug is used for anxiety, agitation and alcohol withdrawal management, according to a Thursday filing with the Shanghai bourse.

The pharmaceutical company has partnered with Jiangsu Enhua Hexin for the drug's exclusive commercialization in mainland China.

Shares of Easton Biopharmaceuticals closed 3% lower Thursday.

Risk Warnings and Disclaimers

Add to Favorites

Easton Biopharmaceuticals Gets Registration Certificate for Dacomitinib Tablets; Shares Jump 5%

MT Newswires

688513

-1.93%

Risk Warnings and Disclaimers

Add to Favorites

Easton Biopharmaceuticals Gets Registration Certificate for Dihydroxypropyl Theophylline Injection

MT Newswires

688513

-1.93%

Chengdu Easton Biopharmaceuticals obtained a drug registration certificate from the Chinese drug administration for dihydroxypropyl theophylline injection, according to a Shanghai Stock Exchange disclosure on Monday.

The drug is used to relieve patients with asthma, wheezing bronchitis, obstructive emphysema, and other conditions causing wheezing, the Chinese drugmaker said.

Risk Warnings and Disclaimers

Add to Favorites

Easton Biopharmaceuticals' Bumetanide Injection Gets Registration Certificate

MT Newswires

688513

-1.93%

Chengdu Easton Biopharmaceuticals obtained a drug registration certificate from the Chinese drug ddministration for the drug, bumetanide injection, according to a Shanghai Stock Exchange disclosure on Saturday.

The drug is used to treat various diseases, including edema diseases, hypertension, hyperkalemia and hypercalcemia, as well as to prevent acute renal failure, the biopharmaceutical company said.

The company's shares closed less than 2% higher.

Risk Warnings and Disclaimers

Add to Favorites

Easton Biopharmaceuticals' Bumetanide Injection Gets Registration Certificate

MT Newswires

688513

-1.93%

The drug is used to treat various diseases, including edema diseases, hypertension, hyperkalemia and hypercalcemia, as well as to prevent acute renal failure, the biopharmaceutical company said.

The company's shares closed less than 2% higher.

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Easton Biopharmaceuticals Gets Registration Certificate for Apalutamide Tablets; Shares Slip 3%

Easton Biopharmaceuticals Gets Registration Certificate for Axitinib Tablets; Shares Down 3%

Easton Biopharmaceuticals Gets China's Regulatory Approval for Psychotropic Drug

Easton Biopharmaceuticals Gets Registration Certificate for Dacomitinib Tablets; Shares Jump 5%

Easton Biopharmaceuticals Gets Registration Certificate for Dihydroxypropyl Theophylline Injection

Easton Biopharmaceuticals' Bumetanide Injection Gets Registration Certificate

Easton Biopharmaceuticals' Bumetanide Injection Gets Registration Certificate

Risk Disclosure